Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

Core Insights - Defence Therapeutics Inc. is advancing its Accum® platform for antibody-drug conjugate (ADC) applications, as discussed in a recent Scientific Advisory Board meeting [1][2]. Group 1: Scientific Advisory Board Meeting - The meeting on January 30, 2026, focused on enhancing the strategic positioning of Accum® for ADC applications, bringing together experts in ADC chemistry, experimental design, and value creation [1][2]. - The discussion aimed to identify critical scientific questions, refine development priorities, and align data generation with the expectations of future clinical and pharmaceutical partners [2]. Group 2: Expert Contributions - Contributions from experts such as Rob Leanna, Danny Chui, and Brendan Hussey provided insights into ADC development, drug-linker chemistry, and clinical advancement, guiding the next phase of Accum® development [3]. - The multidisciplinary dialogue is expected to refine the Accum® ADC development roadmap, aligning platform capabilities with clinical development requirements and partnering considerations [4]. Group 3: Company Overview - Defence Therapeutics is committed to enhancing cancer treatment efficacy and safety through its Accum® precision drug delivery platform, aiming to improve the potency of ADCs and reduce side effects [5]. - The company seeks to collaborate with pharmaceutical and biotech partners to bring transformative therapies to patients [5].